TETarik M. Elsheikh

Tarik M. Elsheikh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tarik M. Elsheikh has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interobserver variation among cytopathologists in the evaluation of oncocytic cell‐predominant thyroid FNA cytology: A validation study of 173 cases with surgical follow‐up and correlation with molecular testing

    by Tarik M. Elsheikh, Erika E. Doxtader, Marko Golusin, Juan Xing, James F. Bena, Lame Balikani

    Background: Interpretation of oncocytic cell‐predominant cytologies (OCP) is very challenging as a majority of those cases are diagnosed as indeterminate, including atypia of undetermined significance (AUS) and follicular neoplasm (FN). The authors previously reported a combination of a four‐risk factor model highly predictive of neoplasia and malignancy that included four cytologic features and nodule size. However, that model was based on a single cytopathologist (CP) review. The current study assessed the reproducibility of previous findings among several CPs in a larger separate patient cohort, correlated with molecular studies. Design: Four CPs independently evaluated cytologic features of 173 surgically confirmed OCP (24 AUS, 149 FN). Nodule size was recorded separately and incorporated into risk factor scores. A subset of 80 cases underwent molecular testing with Afirma or ThyroSeq. Univariable and multivariable logistic regression and ROC analyses were performed. Results: Interobserver agreements were strong for high cellularity, moderate for isolated single cells, and poor for absent colloid and anisonucleosis. Risk factor scores demonstrated strong agreement, high specificity (77%–92%) and low sensitivity (6%–22%). Pathologist agreement did not better predict neoplasm or malignancy. Afirma and ThyroSeq molecular tests had similar performances with overall sensitivity, specificity, and false‐negative rates of 86%, 35%, and 13%–17%, respectively. Conclusion: Cytologic evaluation of OCP was limited by wide interobserver variability and inconsistent associations with outcomes. Agreement of CPs on presence of specific cytologic features did not enhance prediction of neoplasm or malignancy. Molecular testing provided more objective performance displaying high sensitivity; however, specificity was low and FNR was elevated. Clinicians should be made aware of the greater limitations associated with cytology and molecular test results of OCP compared to those reported for their nononcocytic counterparts.

  • Open Access

    Molecular testing and other metrics in thyroid cytology as quality‐assurance measures in evaluating variation among pathologists in the diagnosis of atypia of undetermined significance

    by Tarik M. Elsheikh, Claire Sheen, Timothy Bell, Christine Booth, Erika E. Doxtader, Fatima Hamadeh, Dawn Underwood, Linlin Yang, Rema Chaari

    Background: Atypia of undetermined significance (AUS) is a subjective diagnosis with reported interinstitutional rates ranging from 1% to 20%. The Bethesda System for Reporting Thyroid Cytology (TBS) endorsed ≤10% as an achievable target; however, lowering AUS rates without informed, adjusted diagnostic thresholds can compromise the sensitivity of thyroid cytology. The authors conducted this study to identify quality‐assurance measures that can assess individual pathologist's metrics compared with laboratory averages and published benchmarks and can provide feedback to pathologists on the causes of discrepancy. Methods: AUS rates of 15 cytopathology‐boarded pathologists were correlated with AUS:malignant ratios (AUS:M), histologic risks of malignancy (ROMs), and Afirma molecular‐positive call rates (PCRs), and scatterplots were constructed. The distribution of pathologist TBS diagnostic categories was compared with laboratory averages and correlated with the above metrics. Results: Pathologist AUS rates ranged from 7% to 44% (mean, 19%; 926 of 4801 cases). Average AUS:M and ROM rates were 7.0% and 68% (range, 3%–35% and 25%–87%), respectively. Regression analysis highlighted pathologists' metrics that were outliers. Evaluation of the distribution of individual pathologist’s TBS diagnostic categories identified patterns/trends that explained deviations from laboratory averages, including patterns of significant overcalling of benign as AUS and downgrading diagnoses across multiple TBS categories. Conclusions: Correlation of AUS, AUS:M, and ROM with molecular results, in addition to the distribution of pathologist TBS categories, offer a robust framework for quality assurance that illustrates deviations from target benchmarks, including shifts in interpretations from one TBS category to another. Giving feedback to pathologists regarding their practice patterns can help standardize diagnostic thresholds and meet designated target metrics.


  • Open Access

    Fine‐needle aspiration and effusion cytology of thoracic SMARCA4–deficient undifferentiated tumor and SMARCA4‐deficient non–small cell lung carcinoma: A multi‐institutional experience with 27 patients

    by Nicole Zalles, Sanjay Mukhopadhyay, Swati Satturwar, Sigfred Lajara, Samer Khader, Liron Pantanowitz, Tarik M. Elsheikh

    Background: Thoracic switch/sucrose nonfermentable–related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4 (SMARCA4)–deficient (SD) malignancies, including SD undifferentiated tumor (SD‐UT) and SD non–small cell lung carcinoma (SD‐NSCLC), have been recently described. The cytologic features of these neoplasms in fine‐needle aspiration (FNA) and effusion specimens have rarely been reported in the literature. This study aimed to describe and compare the spectrum of cytologic, immunohistochemical, and clinical features of these high‐grade malignancies recently encountered at the participating institutions.Methods: This study documented clinical and imaging characteristics of tumors from 27 patients. Sixteen cytomorphologic features and immunohistochemical findings were compared between SD‐UT and SD‐NSCLC samples.Results: Twenty three FNAs, two bronchial brushings, and two pleural fluids were evaluated, including 17 SD‐UT cases (mean patient age, 70 years) and 10 SD‐NSCLC cases (mean patient age, 62 years). Both malignancies presented with large thoracic masses and/or hilar/mediastinal lymphadenopathy. All SD‐UT cytologic samples had a discohesive or mixed cohesive–discohesive architecture, and most (13 of 17) showed predominant rhabdoid or mixed rhabdoid–epithelioid features. Most SD‐NSCLC cytologic samples (nine of 10) were either cohesive or mixed cohesive–discohesive and had a predominantly epithelioid morphology (eight of 10). Keratins and claudin‐4 were negative or focally positive in SD‐UT samples, whereas they were diffusely positive in SD‐NSCLC samples. Both malignancies were negative for TTF‐1 and p40/p63 and showed loss of expression of SMARCA4.Conclusions: Although there is considerable clinical and cytopathologic overlap between SD‐UT and SD‐NSCLC, some key features allow for their distinction. SD‐UT is mostly discohesive with rhabdoid or mixed rhabdoid–epithelioid features, whereas SD‐NSCLC often has cohesive epithelioid morphology. The combination of clinical presentation, cytomorphology, and immunohistochemistry is essential for a definitive diagnosis.


  • Open Access

    Atypical squamous cells in urine cytology are associated with a significant risk of high‐grade malignancy

    by Linh Ho, Tarik M. Elsheikh

    Background Atypical squamous cells (ASC) in urine cytology are rarely found, and their clinical significance is not well studied. Previous studies were limited by a small number of cases and a lack of objective grading of ASC and/or their correlation with accompanying urothelial cell abnormality (UCA). Methods The institutional database was searched over 10 years for urine cytology reports containing ASC or from patients who had a concurrent diagnoses of high-grade (HG) urothelial carcinoma with squamous differentiation or squamous carcinoma. ASC were defined as keratinized squamous cells and were subcategorized as reactive, koilocytosis, low-grade (LG) atypia, and HG atypia. Correlations with age, sex, specimen type, accompanying UCA, number of ASC, and the risk of HG malignancy (ROHM) were assessed. Results ASC were present in 0.15% of all urine specimens (123 of 81,018). Slides and clinical follow-up were available on 91 patients (median age, 71 years). LG and HG squamous atypia had ROHMs of 70% and 92%, respectively. ASC accompanied and not accompanied by UCA had ROHMs of 37% and 94%, respectively. Most malignancies (34 of 67; 51%) showed rare ASC in urine. Reactive changes and koilocytosis had 0% ROHM. Conclusions ASC in urine cytology is a significant finding and is associated with a high ROHM. In the absence of accompanying UCA, LG squamous atypia had a lower ROHM than HG atypia. In the presence of UCA, LG and HG squamous atypia had ROHMs of over 90%. These findings suggest that ASC and their grade of atypia should be noted in the cytology report, and clinicians should be made aware of their clinical significance.


  • Open Access

    Papillae, psammoma bodies, and/or many nuclear pseudoinclusions are helpful criteria but should not be required for a definitive cytologic diagnosis of papillary thyroid carcinoma: An institutional experience of 207 cases with surgical follow up

    by Tarik M. Elsheikh, Matthew Thomas, Jennifer Brainard, Jessica Di Marco, Erica Manosky, Bridgette Springer, Dawn Underwood, Deborah J. Chute

    Background: Noninvasive follicular thyroid neoplasm with papillary‐like features (NIFTP) was introduced in 2016 replacing noninvasive follicular variant of papillary thyroid carcinoma, with recommendations to label them “noncancer.” To avoid reducing risk of malignancy (ROM) and overdiagnosing NIFTP as malignant, some authors required restricted cytologic criteria (RC) for a definitive diagnosis of papillary thyroid carcinoma (PTC), including papillae, psammoma bodies. or ≥3 nuclear pseudoinclusions. Since then, NIFTP criteria have been revised, biologic behavior better understood, and incidence reported to be much lower than initially anticipated. This study examines the impact of RC on PTC cytologic diagnoses, ROM, and detection of clinically significant carcinomas (CSC).Materials and Methods: A total of 207 thyroid FNAs originally diagnosed as PTC and suspicious for PTC (SPTC) with surgical follow‐up were evaluated. RC were retrospectively applied to cases as a requirement for diagnosing PTC, and cases that did not meet RC were reclassified as SPTC. ROMs and diagnostic accuracies of pre‐ and post‐RC diagnoses were correlated with followup CSC.Results: RC were met in 118/142 (83%) and 20/65 (31%) of cases originally diagnosed as PTC and SPTC, respectively. Post‐RC, 29% (19/65) of CSC originally diagnosed as SPTC were upgraded to PTC, and 17% (24/142) of CSC originally diagnosed as PTC were downgraded to SPTC. No NIFTPs were diagnosed as malignant.Conclusions: RC should not be required for a definitive diagnosis of PTC when other nuclear features of PTC are diffuse and overt. Applying RC, however, helps the pathologist arrive at a more definitive diagnosis of PTC in suspicious cases.


  • Open Access

    Are there specific cytologic features that can predict BRAFV600E mutational status of papillary thyroid carcinoma in fine‐needle aspiration specimens?

    by Juliann M. Mendes, Tarik M. Elsheikh, Jessica Di Marco, Jennifer Russell, Tatyana Gladkaya, Marlo M. Nicolas, Elisha Clapacs, James F. Bena, John L. McAfee, Maria Luisa C. Policarpio‐Nicolas

    Background: The accurate evaluation of BRAF(V600E) mutation in preoperative fine-needle aspiration cytology (FNAC) specimens is important for making management decisions in thyroid nodules (TNs). The aim of this study was to assess the false-positive and false-negative BRAF(V600E) mutations in thyroid FNAC specimens and their influence on diagnosis of TN. Methods: This prospective study enrolled 292 nodules in 269 patients who underwent BRAF(V600E) mutation analysis using amplification refractory mutation system-quantitative real-time polymerase chain reaction (ARMS-qPCR) both in FNAC specimens and formalin-fixed, paraffin-embedded (FFPE) tissue samples after surgery. The false-positive and false-negative mutations for BRAF(V600E) analysis using ARMS-qPCR in FNAC specimens were recorded, with reference to the results of BRAF(V600E) mutation analysis using ARMS-qPCR in FFPE tissue sample. Diagnostic performances of FNAC, BRAF(V600E) mutation analysis in FNAC specimens, BRAF(V600E) mutation analysis in FFPE tissue sample, and the combination of FNAC and BRAF(V600E) mutation analysis for predicting thyroid malignancy were assessed. Results: The false-positive and false-negative mutations for BRAF(V600E) analysis using ARMS-qPCR in FNAC specimens were 10.1% (19/189) and 7.1% (7/98), respectively. FNAC combined with preoperative BRAF(V600E) mutation analysis significantly increased the diagnostic sensitivity from 75.7% to 92.3%, and accuracy from 78.7% to 90.6% in comparison with FNAC alone (both P < .001). No significant differences were found between the combination of FNAC and BRAF(V600E) mutation analysis in FNAC specimens and the combination of FNAC and BRAF(V600E) mutation analysis in FFPE tissue sample (sensitivity: 92.3% vs 91.9%; accuracy: 90.6% vs 91.3%; both P > .05). Conclusions: FNAC combined with preoperative BRAF(V600E) mutation analysis can significantly increase the diagnostic performance in comparison with FNAC alone. False-positive and false-negative BRAF(V600E) mutation results are found in preoperative FNAC specimens, whereas it does not affect the overall auxiliary diagnosis of TNs.


  • Benign

    by Tarik Elsheikh, SoonWon Hong, Christian Nasr, Elena Vigliar


  • Non-Neoplastic

    by William C. Faquin, Massimo Bongiovanni, Fabiano Callegari, Tarik M. Elsheikh, Daniel F. I. Kurtycz, Oscar Lin, Ravi Mehrotra, Marc P. Pusztaszeri, Judy Qiuying Shi, Zhihui Zhang

  • Open Access

    Hürthle cell‐predominant thyroid fine needle aspiration cytology: A four risk‐factor model highly accurate in excluding malignancy and predicting neoplasm

    by Lisi Yuan, Christian Nasr, James F. Bena, Tarik M. Elsheikh

    Background: Interpretation of Hürthle cell‐predominant cytologies (HCP) is very challenging as a majority is diagnosed as indeterminate. Prior studies have reported various cytologic features to help distinguish non‐neoplastic (NN) from neoplastic and malignant lesions but had contradicting results. Our aim was to identify risk factors predictive of neoplasm and/or malignancy by correlating cytologic features with clinical and ultrasound findings.Methods: Sixty‐nine HCP cases with surgical follow‐up were identified, including 35 NN, 20 adenomas, and 14 carcinomas. Ultrasound data were recorded utilizing Thyroid Imaging Reporting and Data System (TI‐RADS) and American Thyroid Association (ATA) scoring systems. Sixteen cytologic criteria were evaluated and semi‐quantitatively scored. Data were assessed by univariable, multivariable and stepwise logistic regression analysis; and statistical significance achieved at P‐value <0.05.Results: On univariable analysis, significant predictors of neoplasm were high cellularity, isolated single cells, absent colloid, non‐uniform HC population (anisonucleosis), larger nodule size, and higher ATA score. Large‐cell dysplasia and transgressing blood vessels were not found to be significant factors. Multivariable analysis identified a combination of four risk factors (high cellularity, anisonucleosis, absent colloid, and size ≥2.9 cm) that was associated with neoplasm in 10/11 patients. None of 15 patients with zero or 1 out of 4 risk factors had malignancy or neoplasm on follow‐up. This model also significantly outperformed ATA and TI‐RADS scoring systems.Conclusion: In the absence of four or three risk factors, the model excluded malignancy and neoplasm in all patients. The presence of all four factors predicted neoplasm and malignancy in 91% and 46% of cases, respectively.